Fitoterapia Chinesa no tratamento complementar da Síndrome Metabólica: uma revisão sistemática
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Apr 15, 2023
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Descrever a relação dose - resposta do efeito da ação terapêutica da Fitoterapia Chinesa como tratamento complementar ou isolado na Síndrome Metabólica (SM). Métodos: A busca da literatura foi realizada nas bases de dados MEDLINE/PubMed, Embase, Cochrane, BVS e ClinicalTrials.gov. A literatura cinzenta foi pesquisada no Google Scholar e Scopus. A análise metodológica e risco de viés foram realizados através da ferramenta Risk of Bias (RoB2) tool da Cochrane, e análise das limitações metodológicas através do CASP Randomised Controlled Trial Standard Checklist. A análise da evidência qualitativa foi realizada através do GRADE-CERqual. O protocolo desta revisão sistemática foi registrado no PROSPERO com CRD42021281682. Resultados: Nove ensaios clínicos randomizados, todos revisados por pares, foram incluídos nesta revisão para a síntese qualitativa. Em 88,8% dos estudos incluídos a Fitoterapia Chinesa demonstrou exercer um efeito benéfico no controle da SM. Quanto a análise da evidência qualitativa os estudos apresentaram confiança de moderada a baixa. Considerações finais: A Fitoterapia Tradicional Chinesa pode controlar a SM, quando usada de forma complementar ou isolada. Todavia, o mecanismo de ação desses fitoterápicos ainda precisa ser mais investigado por ensaios clínicos em larga escala.
##plugins.themes.bootstrap3.article.details##
Como Citar
CamposL. da S., SoaresL. G., LeonelC. F. S., RosaR. D. da, & BykJ. (2023). Fitoterapia Chinesa no tratamento complementar da Síndrome Metabólica: uma revisão sistemática. Revista Eletrônica Acervo Saúde, 23(4), e12022. https://doi.org/10.25248/reas.e12022.2023
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. AMERICAN DIABETES ASSOCIATION (ADA). Standards of medical care in diabetes. Diabetes Care. 2016. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714725/. Acessado em: 25 de julho de 2022.
2. BASU A, et al. Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition. 2011; 27(2): 206-13.
3. BRASIL. Ministério da Saúde, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: elaboração de revisão sistemática e metanálise de ensaios clínicos randomizados/ Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Ciência e Tecnologia.Brasília: Editora do Ministério da Saúde, 2012. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_elaboracao_sistematica.pdf. Acessado em: 15 de março de 2022.
4. CAO C e SU M. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Experimental and therapeutic medicine, 2019; 17(4): 3009-3014.
5. CHEN Y, et al. Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: a randomized, placebo-controlled trial. J Integr Med., 2013; 11(3): 184-94.
6. CHEN X. Effects of traditional Chinese medicine combined with general lifestyle interfering the patients with impaired glucose tolerance combined metabolic syndrome (Qi and Yin deficiency syndrome). Beijing, China: 2011.
7. QUALITATIVE APPRAISAL CHECKLIST FOR QUALITATIVE RESEARCH (CASP), 2011. Disponível: http://www.casp-uk.net/#!casp-tools-checklists/c18f8. Acessado em: 15 de Agosto de 2022.
8. COZMA A, et al. Determining factors of arterial stiffness in subjects with metabolic syndrome. Metabolic syndrome and related disorders, 2018; 16(9): 490-496-10.
9. FUJIOKA K. Metabolic syndrome treatment strategies. Pharmacotherapy, 2006; 26(12): 222-226.
10. FUJIOKA K, et al. The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome. J Med Food, 2006; 9(1): 49-54.
11. GE H, et al. The prevalence and associated factors of metabolic syndrome in Chinese aging population. Scientific Reports, 2020; 10(1): 1-10.
12. HAN M, et al. The Efficacy of Acupuncture on Anthropometric Measures and the Biochemical Markers for Metabolic Syndrome: A Randomized Controlled Pilot Study. Evid Based Complement Alternat Med., 2017; e8598210.
13. HUNG HH, et al. Evaluation of the efficacy of Chinese herbal medicine and acupuncture for the prevention of mental disorders in interstitial cystitis patients. Medicine, 2020; 99(30).
14. HORÁKOVÁ D, et al. Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population. Medicina (Kaunas), 2019; 55(5): 158.
15. HIRODE G e WONG RJ. Trends in the prevalence of metabolic syndrome in the United States. Jama, 2020; 323(24): 2526-2528.
16. HUANG KF, et al. Studies on the inhibitory effect of Graptopetalum paraguayense E. Walther extracts on mushroom tyrosinase. Food Chemistry. 2005; 89(4): 583–587.
17. IKEDA Y, et al. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J. 2001; 48(1): 1-6.
18. JUNG JY, et al. Association of fasting glucose and glycated hemoglobin with the long-term risk of incident metabolic syndrome: Korean Genome and Epidemiology Study (KoGES). Acta Diabetol, 2019; 56(5): 551-559.
19. JANG S, et al. Herbal Medicines for Treating Metabolic Syndrome: A Systematic Review of Randomized Controlled Trials. Evid Based Complement Alternat Med., 2016; e5936402.
20. KAUR J. A comprehensive review on metabolic syndrome. Cardiol Res Pract., 2014; 9(43): 162.
21. KLUPP NL, et al. A double blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep. 2016; 11(6): e29540.
22. KARPE F, et al. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes, 2011; 60(10): 2441-2449.
23. LAKKA HM, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002; 288(21): 2709-16.
24. LIU L, et al. Effect of Hedan Tablets on Body Weight and Insulin Resistance in Patients with Metabolic Syndrome. Obes Facts, 2022; 15(2): 180-185.
25. LIAN J, et al. Clinical observation on effect of Yitangkang treating MS with IGR from the BMI levels. Journal of Liaoning University of Traditional Chinese Medicine, 2012; 14:27–30.
26. LAM DW, et al. Metabolic Syndrome. 2019.
27. LEWIN S, et al. Using Qualitative Evidence in Decision Making for Health and Social Interventions: An Approach to Assess Confidence in Findings from Qualitative Evidence Syntheses (GRADE-CERQual). PLoS Med. 2015; 12(10): 1–18.
28. LIM S, ECKEL RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord., 2014; 15(4): 329-41.
29. ONG KL, et al. Using glycosylated hemoglobin to define the metabolic syndrome in United States adults. Diabetes Care, 2010;33 (8): e1856-8.
30. PAGE MJ, et al. The PRISMA statement: An updated guideline for reporting systematic reviews. The BMJ, 2020; 372.
31. RODRIGUES MC, et al. Prevalence and factors associated with metabolic syndrome in a vulnerable population in northern Brazil: a cross-sectional study. Journal of Human Growth and Development, 2021; 31(2): 291-301.
32. SAMSON SL, GARBER AJ. Metabolic syndrome. Endocrinology and Metabolism Clinics, 2014; 43(1): 1-23.
33. STERNE J, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019; e366.
34. SUN F, et al. A Placebo-Controlled Study on the Treatment of Metabolic Syndrome of Qi Stagnation and Dampness Obstruction Related to Atypical Antipsychotics with Traditional Chinese Medicine (TCM). Evid Based Complement Alternat Med., 2020; e5103046.
35. TIAN-ZHAN W, et al. Synergistic effects of Yiqi Huazhuo Gushen herbal formula and valsartan on metabolic syndrome complicated with microalbuminuria. Tropical Journal of Pharmaceutical Research, 2019; 18(1).
36. VIEIRA BA, et al. Timing and type of alcohol consumption and the metabolic syndrome-ELSA-Brasil. PLoS One, 2016; 11(9): e0163044.
37. VIEIRA EC, et al. Prevalence and factors associated with the Metabolic Syndrome in elderly users of the Unified Health System. Brazilian Journal of Epidemiology, 2014; (17): 805-817.
38. WHITE LS, et al. The gut microbiota: cause and cure of gut diseases. Medical Jour of Aus, 2018; 209(7): 312-317.
39. YEN C, et al. Effects of water extracts of Graptopetalum paraguayense on blood pressure, fasting glucose, and lipid profiles of subjects with metabolic syndrome. Biomed Res Int., 2013; e809234.
40. YIN J, et al. Traditional Chinese medicine in treatment of metabolic syndrome. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabol Dis, 2008; 8(2): 99-111.
41. YU X, et al. The efficacy and safety of the Chinese herbal formula, JTTZ, for the treatment of type 2 diabetes with obesity and hyperlipidemia: a multicenter randomized, positive-controlled, open-label clinical trial. International Journal of Endocrinology, 2018; e9519231.
2. BASU A, et al. Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition. 2011; 27(2): 206-13.
3. BRASIL. Ministério da Saúde, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: elaboração de revisão sistemática e metanálise de ensaios clínicos randomizados/ Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Ciência e Tecnologia.Brasília: Editora do Ministério da Saúde, 2012. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_elaboracao_sistematica.pdf. Acessado em: 15 de março de 2022.
4. CAO C e SU M. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Experimental and therapeutic medicine, 2019; 17(4): 3009-3014.
5. CHEN Y, et al. Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: a randomized, placebo-controlled trial. J Integr Med., 2013; 11(3): 184-94.
6. CHEN X. Effects of traditional Chinese medicine combined with general lifestyle interfering the patients with impaired glucose tolerance combined metabolic syndrome (Qi and Yin deficiency syndrome). Beijing, China: 2011.
7. QUALITATIVE APPRAISAL CHECKLIST FOR QUALITATIVE RESEARCH (CASP), 2011. Disponível: http://www.casp-uk.net/#!casp-tools-checklists/c18f8. Acessado em: 15 de Agosto de 2022.
8. COZMA A, et al. Determining factors of arterial stiffness in subjects with metabolic syndrome. Metabolic syndrome and related disorders, 2018; 16(9): 490-496-10.
9. FUJIOKA K. Metabolic syndrome treatment strategies. Pharmacotherapy, 2006; 26(12): 222-226.
10. FUJIOKA K, et al. The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome. J Med Food, 2006; 9(1): 49-54.
11. GE H, et al. The prevalence and associated factors of metabolic syndrome in Chinese aging population. Scientific Reports, 2020; 10(1): 1-10.
12. HAN M, et al. The Efficacy of Acupuncture on Anthropometric Measures and the Biochemical Markers for Metabolic Syndrome: A Randomized Controlled Pilot Study. Evid Based Complement Alternat Med., 2017; e8598210.
13. HUNG HH, et al. Evaluation of the efficacy of Chinese herbal medicine and acupuncture for the prevention of mental disorders in interstitial cystitis patients. Medicine, 2020; 99(30).
14. HORÁKOVÁ D, et al. Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population. Medicina (Kaunas), 2019; 55(5): 158.
15. HIRODE G e WONG RJ. Trends in the prevalence of metabolic syndrome in the United States. Jama, 2020; 323(24): 2526-2528.
16. HUANG KF, et al. Studies on the inhibitory effect of Graptopetalum paraguayense E. Walther extracts on mushroom tyrosinase. Food Chemistry. 2005; 89(4): 583–587.
17. IKEDA Y, et al. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J. 2001; 48(1): 1-6.
18. JUNG JY, et al. Association of fasting glucose and glycated hemoglobin with the long-term risk of incident metabolic syndrome: Korean Genome and Epidemiology Study (KoGES). Acta Diabetol, 2019; 56(5): 551-559.
19. JANG S, et al. Herbal Medicines for Treating Metabolic Syndrome: A Systematic Review of Randomized Controlled Trials. Evid Based Complement Alternat Med., 2016; e5936402.
20. KAUR J. A comprehensive review on metabolic syndrome. Cardiol Res Pract., 2014; 9(43): 162.
21. KLUPP NL, et al. A double blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep. 2016; 11(6): e29540.
22. KARPE F, et al. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes, 2011; 60(10): 2441-2449.
23. LAKKA HM, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002; 288(21): 2709-16.
24. LIU L, et al. Effect of Hedan Tablets on Body Weight and Insulin Resistance in Patients with Metabolic Syndrome. Obes Facts, 2022; 15(2): 180-185.
25. LIAN J, et al. Clinical observation on effect of Yitangkang treating MS with IGR from the BMI levels. Journal of Liaoning University of Traditional Chinese Medicine, 2012; 14:27–30.
26. LAM DW, et al. Metabolic Syndrome. 2019.
27. LEWIN S, et al. Using Qualitative Evidence in Decision Making for Health and Social Interventions: An Approach to Assess Confidence in Findings from Qualitative Evidence Syntheses (GRADE-CERQual). PLoS Med. 2015; 12(10): 1–18.
28. LIM S, ECKEL RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord., 2014; 15(4): 329-41.
29. ONG KL, et al. Using glycosylated hemoglobin to define the metabolic syndrome in United States adults. Diabetes Care, 2010;33 (8): e1856-8.
30. PAGE MJ, et al. The PRISMA statement: An updated guideline for reporting systematic reviews. The BMJ, 2020; 372.
31. RODRIGUES MC, et al. Prevalence and factors associated with metabolic syndrome in a vulnerable population in northern Brazil: a cross-sectional study. Journal of Human Growth and Development, 2021; 31(2): 291-301.
32. SAMSON SL, GARBER AJ. Metabolic syndrome. Endocrinology and Metabolism Clinics, 2014; 43(1): 1-23.
33. STERNE J, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019; e366.
34. SUN F, et al. A Placebo-Controlled Study on the Treatment of Metabolic Syndrome of Qi Stagnation and Dampness Obstruction Related to Atypical Antipsychotics with Traditional Chinese Medicine (TCM). Evid Based Complement Alternat Med., 2020; e5103046.
35. TIAN-ZHAN W, et al. Synergistic effects of Yiqi Huazhuo Gushen herbal formula and valsartan on metabolic syndrome complicated with microalbuminuria. Tropical Journal of Pharmaceutical Research, 2019; 18(1).
36. VIEIRA BA, et al. Timing and type of alcohol consumption and the metabolic syndrome-ELSA-Brasil. PLoS One, 2016; 11(9): e0163044.
37. VIEIRA EC, et al. Prevalence and factors associated with the Metabolic Syndrome in elderly users of the Unified Health System. Brazilian Journal of Epidemiology, 2014; (17): 805-817.
38. WHITE LS, et al. The gut microbiota: cause and cure of gut diseases. Medical Jour of Aus, 2018; 209(7): 312-317.
39. YEN C, et al. Effects of water extracts of Graptopetalum paraguayense on blood pressure, fasting glucose, and lipid profiles of subjects with metabolic syndrome. Biomed Res Int., 2013; e809234.
40. YIN J, et al. Traditional Chinese medicine in treatment of metabolic syndrome. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabol Dis, 2008; 8(2): 99-111.
41. YU X, et al. The efficacy and safety of the Chinese herbal formula, JTTZ, for the treatment of type 2 diabetes with obesity and hyperlipidemia: a multicenter randomized, positive-controlled, open-label clinical trial. International Journal of Endocrinology, 2018; e9519231.